Cholesterol-lowering drug slows progression of eye disease in people with diabetes: Clinical trial

Primary composite outcome of referable diabetic retinopathy or maculopathy, or treatment thereof, with intravitreal injection of medication, retinal laser therapy, or vitrectomy. The inset graph shows the same data on an expanded y axis. Credit: NEJM Evidence (2024). DOI: 10.1056/EVIDoa2400179 The LENS trial has demonstrated that fenofibrate, a drug usually used to lower cholesterol, reduces the risk of progression of diabetic retinopathy by 27%. The results were announced at the American Diabetes Association Scientific Sessions and published in a paper titled, “Effect of Fenofibrate on Progression of Diabetic Retinopathy,” published Read More

Related posts:

  1. Clinical trial shows promising results in a two-drug combination that curbs methamphetamine use
  2. AI model to improve clinical trial recruitment for eye disease
  3. New cancer treatment slows progression of aggressive neuroendocrine tumors, study finds
  4. Major trial looks at most effective speech therapy for people with Parkinson’s disease
  5. Clinical trial investigates using electronic alerts to help control blood pressure
  6. Breakthrough brain recording device receives FDA approval for a clinical trial
  7. First-of-its-kind clinical trial eliminates or shrinks melanoma tumors in 70% of patients
  8. Clinical trial reports promising new treatment reduces suffering in Sanfilippo syndrome

Leave a Reply

Your email address will not be published. Required fields are marked *